Citations

Clear

73 citation(s) found for "Chia, Nicholas".

Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS
Redenbaugh, Vyanka , McCombe, Jennifer A. , Tillema, Jan‐Mendelt , Chen, John J. , López‐Chiriboga, A. Sebastian , Sechi, Elia , Pittock, Sean J, Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Chia, Nicholas H , Lopez-Chiriboga, A Sebastian , Sechi, Elia , Pittock, Sean J , Flanagan, E P , Chen, John J , Redenbaugh, Vyanka , Chia, Nicholas , Cacciaguerra, Laura , Hacohen, Yael , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | May 23, 2023 | Volume: 29 | Issue: 7 | Pages: 799-808

10.1177/13524585231166834 | PMID 37218499 Get It

Background: Magnetic resonance imaging (MRI) T2-lesions resolve more often in myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) than aquaporin-4 IgG-positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD) and multiple sclerosis (MS) in adults but few studies analyzed children. Objective: The main objective of this study is to investigate MRI T2-lesion evolution in pediatric MOGAD, AQP4 + NMOSD, and MS. Methods: Inclusion criteria were as follows: (1) first clinical attack; (2) abnormal MRI (⩽6 weeks); (3) follow-up MRI beyond 6 months without relapses in that region; and (4) age < 18 years. An index T2-lesion (symptomatic/largest) was identified, and T2-lesion resolution or persistence on follow-up MRI was determined. Results: We included 56 patients (MOGAD, 21; AQP4 + NMOSD, 8; MS, 27) with 69 attacks. Index T2-lesion resolution was more frequent in MOGAD (brain 9 of 15 [60%]; spine 8 of 12 [67%]) than AQP4 + NMOSD (brain 1 of 4 [25%]; spine 0 of 7 [0%]) and MS (brain 0 of 18 [0%]; spine 1 of 13 [8%]), p < 0.01. Resolution of all T2-lesions occurred more often in MOGAD (brain 6 of 15 [40%]; spine 7 of 12 [58%]) than AQP4 + NMOSD (brain 1 of 4 [25%]; spine 0 of 7 [0%]), and MS (brain 0 of 18 [0%]; spine 1 of 13 [8%]), p < 0.01. Reductions in median index T2-lesion area were greater in MOGAD (brain, 305 mm; spine, 23 mm) than MS (brain, 42 mm [ p<0.001]; spine, 10 mm [ p<0.001]) without differing from AQP4 + NMOSD (brain, 133 mm [ p=0.42]; spine, 19.5 mm [ p=0.69]). Conclusion: In children, MRI T2-lesions resolved more often in MOGAD than AQP4 + NMOSD and MS which is similar to adults suggesting these differences are related to pathogenesis rather than age.
Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria
Chia, Nicholas , McKeon, Andrew , Dalakas, Marinos C. , Bower, James H., Klassen, Bryan T. , Dubey, Divyanshu , Zalewski, Nicholas L. , Duffy, Dustin, Pittock, Sean J. , Ζεκερίδου, Αναστασία , Pittock, S J , Chia, Nicholas H , Dubey, Divyanshu , Zekeridou, Anastasia , McKeon, Andrew , Flanagan, Eoin P. , Dubey, Divyanshu

Mayo Clinic

Annals of Clinical and Translational Neurology | May 22, 2023 | Volume: 10 | Issue: 7 | Pages: 1083-1094

10.1002/acn3.51791 | PMID 37212351 Get It

AbstractBackgroundStiff person spectrum disorder (SPSD) is heterogeneous, and accurate diagnosis can be challenging.MethodsPatients referred for diagnosis/suspicion of SPSD at the Mayo Autoimmune Neurology Clinic from July 01, 2016, to June 30, 2021, were retrospectively identified. SPSD diagnosis was defined as clinical SPSD manifestations confirmed by an autoimmune neurologist and seropositivity for high‐titer GAD65‐IgG (>20.0 nmol/L), glycine‐receptor‐IgG or amphiphysin‐IgG, and/or confirmatory electrodiagnostic studies (essential if seronegative). Clinical presentation, examination, and ancillary testing were compared to differentiate SPSD from non‐SPSD.ResultsOf 173 cases, 48 (28%) were diagnosed with SPSD and 125 (72%) with non‐SPSD. Most SPSD were seropositive (41/48: GAD65‐IgG 28/41, glycine‐receptor‐IgG 12/41, amphiphysin‐IgG 2/41). Pain syndromes or functional neurologic disorder were the most common non‐SPSD diagnoses (81/125, 65%). SPSD patients more commonly reported exaggerated startle (81% vs. 56%, p = 0.02), unexplained falls (76% vs. 46%, p = 0.001), and other associated autoimmunity (50% vs. 27%, p = 0.005). SPSD more often had hypertonia (60% vs. 24%, p < 0.001), hyperreflexia (71% vs. 43%, p = 0.001), and lumbar hyperlordosis (67% vs. 9%, p < 0.001) and less likely functional neurologic signs (6% vs. 33%, p = 0.001). SPSD patients more frequently had electrodiagnostic abnormalities (74% vs. 17%, p < 0.001), and at least moderate symptomatic improvement with benzodiazepines (51% vs. 16%, p < 0.001) or immunotherapy (45% vs. 13% p < 0.001). Only 4/78 non‐SPSD patients who received immunotherapy had alternative neurologic autoimmunity.InterpretationMisdiagnosis was threefold more common than confirmed SPSD. Functional or non‐neurologic disorders accounted for most misdiagnoses. Clinical and ancillary testing factors can reduce misdiagnosis and exposure to unnecessary treatments. SPSD diagnostic criteria are suggested.
Abstract 806: Enhancer deregulation inTET2-mutant clonal hematopoiesis is associated with increased COVID-19 severity and mortality
Ben-Crentsil, Nana Adjoa , Geyer, Susan M. , Finke, Christy M. , Mangaonkar, Abhishek A. , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik, Schwager, Susan M., Harrington, Jonathan J. , Snyder, Melissa R. , Wieben, Eric D. , Padron, Eric , Patnaik, Mrinal M. , Binder, Moritz , Lasho, Terra L. , Ismail, Wazim Mohammed , Fernandez, Jenna , Kim, Minsuk , Mazzone, Amelia , Lee, Jeong‐Heon , Kim, Kwan‐Hyun , Munankarmy, Amik , Droin, Nathalie , Solary, Éric , Robertson, Keith D. , Chia, Nicholas , Gaspar‐Maia, Alexandre

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 806-806

10.1158/1538-7445.am2023-806 Get It

Abstract Background: COVID-19 causes significant morbidity and mortality, albeit with considerable heterogeneity among affected individuals. It remains unclear which host factors determine disease severity and survival. Given the propensity of clonal hematopoiesis (CH) to promote inflammation in healthy individuals, we investigated its effect on COVID-19 outcomes. Methods: We performed a multi-omics interrogation of the genome, epigenome, transcriptome, and proteome of peripheral blood mononuclear cells from COVID-19 patients (n=227). We obtained clinical data, laboratory studies, and survival outcomes. We determined CH status and TET2-related DNA methylation. We performed single-cell proteogenomics to understand clonal composition in relation to cell phenotype. We interrogated single-cell gene expression in isolation and in conjunction with DNA accessibility. We integrated these multi-omics data to understand the effect of CH on clonal composition, gene expression, methylation of cis-regulatory elements, and lineage commitment in COVID-19 patients. We performed shRNA knockdowns to validate the effect of one candidate transcription factor in myeloid cell lines. Results: The presence of CH was strongly associated with COVID-19 severity and all-cause mortality, independent of age (HR 3.48, 95% CI 1.45-8.36, p=0.005). Differential methylation of promoters and enhancers was prevalent in TET2-mutant, but not DNMT3A-mutant CH. TET2-mutant CH was associated with enhanced classical/intermediate monocytosis and single-cell proteogenomics confirmed an enrichment of TET2 mutations in these cell types. We identified cell-type specific gene expression changes associated with TET2 mutations in 102,072 single cells (n=34). Single-cell RNA-seq confirmed the skewing of hematopoiesis towards classical and intermediate monocytes and demonstrated the downregulation of EGR1 (a transcription factor important for monocyte differentiation) along with up-regulation of the lncRNA MALAT1 in monocytes. Combined scRNA-/scATAC-seq in 43,160 single cells (n=18) confirmed the skewing of hematopoiesis and up-regulation of MALAT1 in monocytes along with decreased accessibility of EGR1 motifs in known cis-regulatory elements. Using myeloid cell lines for functional validation, shRNA knockdowns of EGR1 confirmed the up-regulation of MALAT1 (in comparison to wildtype controls). Conclusions: CH is an independent prognostic factor in COVID-19 and skews hematopoiesis towards monocytosis. TET2-mutant CH is characterized by differential methylation and accessibility of enhancers binding myeloid transcriptions factors including EGR1. The ensuing loss of EGR1 expression in monocytes causes MALAT1 overexpression, a factor known to promote monocyte differentiation and inflammation. These data provide a mechanistic insight to the adverse prognostic impact of CH in COVID-19. Citation Format: Moritz Binder, Terra L. Lasho, Wazim Mohammed Ismail, Nana A. Ben-Crentsil, Jenna A. Fernandez, Minsuk Kim, Susan M. Geyer, Amelia Mazzone, Christy M. Finke, Abhishek A. Mangaonkar, Jeong-Heon Lee, Kwan Hyun Kim, Vernadette A. Simon, Fariborz Rakhshan Rohakthar, Amik Munankarmy, Susan M. Schwager, Jonathan J. Harrington, Melissa R. Snyder, Nathalie M. Droin, Eric Solary, Keith D. Robertson, Eric D. Wieben, Eric Padron, Nicholas Chia, Alexandre Gaspar-Maia, Mrinal M. Patnaik. Enhancer deregulation inTET2-mutant clonal hematopoiesis is associated with increased COVID-19 severity and mortality [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 806.
Clinical Reasoning: New-Onset Diplopia and Headache in a Patient With Metastatic Breast Cancer
Rizzo, Skylar A. , Trejo‐Lopez, Jorge , Toledano, Michel , Trejo-Lopez, Jorge A, Chia, Nicholas H , Flanagan, Eoin P. , Chia, Nicholas

Mayo Clinic

Neurology | February 20, 2023 | Volume: 100 | Issue: 19 | Pages: 927-931

10.1212/wnl.0000000000206856 | PMID 36805434 Get It

Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis
Chia, Nicholas , Redenbaugh, Vyanka , Chen, John J. , Pittock, Sean J, Pittock, Sean J. , Kunchok, Amy , Pittock, S J , Chia, Nicholas H , Pittock, Sean J , Flanagan, E P , Chen, John J , Redenbaugh, Vyanka , Flanagan, Eoin P.

Mayo Clinic

Multiple Sclerosis Journal | January 24, 2023 | Volume: 29 | Issue: 6 | Pages: 748-752

10.1177/13524585221150743 | PMID 36691800 Get It

Background: Data on corpus callosum involvement in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited. Objective: The objective of the study was to compare callosal lesions in MOGAD, multiple sclerosis (MS), and aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Results: Callosal lesion frequency was similar in MOGAD (38/171 (22%)), MS (24/72 (33%)), and AQP4+NMOSD (18/63 (29%)). Clinical phenotypes included encephalopathy (47%) and focal supratentorial (21%) or infratentorial (45%) deficits. None had callosal-disconnection syndromes. Maximal callosal-T2-lesion diameter (median (range)) in millimeter was similar in MOGAD (21 (4–77)) and AQP4+NMOSD (22 (5–49); p = 0.93) but greater than in MS (10.5 (2–64)). Extracallosal extension (21/38 (55%)) and T2-lesion resolution (19/34 (56%)) favored MOGAD. Conclusions: Despite similar frequency and imaging overlap, larger lesions, sagittal midline involvement, and lesion resolution favored MOGAD.
Intranasal vaccination with live attenuated influenza vaccine increases diversity of the human nasal microbiome (VAC8P.1001)
Lambert, Nathaniel, Salk, Hannah M., Kennedy, Rick, Grill, Diane E. , Kennedy, Rick, Chia, Nicholas , Jacobson, Robert M. , Poland, Gregory A.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 192 | Issue: Supplement_1 | Pages: 142.7-142.7

10.4049/jimmunol.192.supp.142.7 Get It

Abstract Pre and post-licensure studies have supported the safety of the intranasally administered live, attenuated influenza vaccine (LAIV). The objective of this study was to measure changes to the nasal microbiome in subjects who received LAIV. We hypothesized that administration would result in only a transient alteration of the nasal microbiome. To test this hypothesis, we swabbed the anterior nares just before vaccination (Day 0), and on Day 7 and Day 28. We performed next-generation sequencing on amplified 16s rRNA genes. There was a significant increase in alpha diversity (Observed, CHAO, and ACE) from Days 0 to 7 (p = 0.02, 0.00, 0.01; respectively) and Days 0 to 28 (p = 0.05, 0.03, 0.05; respectively). When measuring differences in specific observed taxanomic units (OTUs), we identified a significant increase in Flavobacteriaceae and Enterobacteriaceae after vaccination. These data suggest that LAIV may increase the ability of these less abundant OTUs to establish a community niche and, therefore, could be clinically relevant. We have begun to investigate the second objective of this study, which is to correlate microbiome composition with mucosal immunity to influenza virus. To our knowledge, this is the first study to investigate LAIV-induced alterations to the human microbiome. These data may lead to a better understanding of the influences of the host microbiome on the response to vaccine, and perhaps infection.
Acinetobacter baumannii Genomic Sequence-Based Core Genome Multilocus Sequence Typing Using Ridom SeqSphere+ and Antimicrobial Susceptibility Prediction in ARESdb
Fida, Madiha , Beisken, Stephan , Posch, Andreas E. , Jeraldo, Patricio , Zinsmaster, Nicole M., Patel, Robin , Jeraldo, Patricio R , Murphy, Matthew P., Patel, Robin , Fida, Madiha , Cunningham, Scott A. , Chia, Nicholas , Murphy, Matthew P.

Mayo Clinic

Journal of Clinical Microbiology | July 12, 2022 | Volume: 60 | Issue: 8 | Pages: No page available

10.1128/jcm.00533-22 | PMID 35862760 Get It

Whole-genome sequencing (WGS) is rapidly replacing traditional typing methods for the investigation of infectious disease outbreaks. Additionally, WGS data are being used to predict phenotypic antimicrobial susceptibility. Acinetobacter baumannii , which is often multidrug-resistant, is a significant culprit in outbreaks in health care settings.
Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma
Wongjarupong, Nicha , Yang, Lu , Johnson, Stephen , Yao, Janet , Harrington, Sean C., Nordyke, Cynthia K., Eaton, John E. , Gossard, Andrea A., Oli, Sharad , Ali, Hamdi A. , Lavu, Sravanthi , Giama, Nasra H., Hassan, Fatima, Ali, Hawa M. , Gores, Gregory J. , Topazian, Mark , Kashyap, Purna , Roberts, Lewis R. , Gores, Gregory J. , Yao, Janet Z, Hassan, Fatima A, Enders, Felicity T, Roberts, Lewis R , Miyabe, Katsuyuki , Chandrasekhara, Vinay , Chen, Jun , Chia, Nicholas , Walther-António, Marina , Enders, Felicity , Ilyas, Sumera I.

Mayo Clinic

Cancers | April 24, 2022 | Volume: 14 | Issue: 9 | Pages: 2120

10.3390/cancers14092120 | PMID 35565248 Get It

Background: Primary sclerosing cholangitis (PSC) is a major risk factor for cholangiocarcinoma (CCA). We investigated biliary and fecal microbiota to determine whether specific microbes in the bile or stool are associated with PSC or CCA. Methods: Bile was obtained from 32 patients with PSC, 23 with CCA with PSC, 26 with CCA without PSC, and 17 controls. Over 90% of bile samples were from patients with perihilar CCA. Stool was obtained from 31 patients with PSC (11 were matched to bile), 16 with CCA with PSC (10 matched to bile), and 11 with CCA without PSC (6 matched to bile). Microbiota composition was assessed using 16SrRNA-marker-based sequencing and was compared between groups. Results: Bile has a unique microbiota distinguished from negative DNA controls and stool. Increased species richness and abundance of Fusobacteria correlated with duration of PSC and characterized the biliary microbiota in CCA. Stool microbiota composition showed no significant differences between groups. Conclusions: We identified a unique microbial signature in the bile of patients with increased duration of PSC or with CCA, suggesting a role for microbiota-driven inflammation in the pathogenesis and or progression to perihilar CCA. Further studies are needed to test this hypothesis.
Optimizing Nanopore Sequencing for Rapid Detection of Microbial Species and Antimicrobial Resistance in Patients at Risk of Surgical Site Infections
Whittle, Emma , Jeraldo, Patricio , Nelson, Heidi , Kendrick, Michael L. , Patel, Robin , Truty, Mark J. , Yonkus, Jennifer A. , Jeraldo, Patricio R , Alva-Ruiz, Roberto, Grys, Thomas E. , Patel, Robin , Alva‐Ruiz, Roberto , Chia, Nicholas

Mayo Clinic

mSphere | February 16, 2022 | Volume: 7 | Issue: 1 | Pages: No page available

10.1128/msphere.00964-21 | PMID 35171692 Get It

Surgical site infections (SSI) are a significant burden to patients and health care systems. They increase mortality rates, length of hospital stays, and associated health care costs.
Transcriptomic analysis of Streptococcus agalactiae periprosthetic joint infection
Masters, Thao , Greenwood‐Quaintance, Kerryl E. , Johnson, Stephen , Pu, Meng , Patel, Robin , Cho, Hye-Kyung, Jeraldo, Patricio R , Patel, Robin , Cho, Hye-Kyung , Jeraldo, Patricio , Chia, Nicholas , Abdel, Matthew P.

Mayo Clinic

MicrobiologyOpen | December 17, 2021 | Volume: 10 | Issue: 6 | Pages: No page available

10.1002/mbo3.1256 | PMID 34964296 Get It

AbstractAlthough Streptococcus agalactiae periprosthetic joint infection (PJI) is not as prevalent as staphylococcal PJI, invasive S. agalactiae infection is not uncommon. Here, RNA‐seq was used to perform transcriptomic analysis of S. agalactiae PJI using fluid derived from sonication of explanted arthroplasties of subjects with S. agalactiae PJI, with results compared to those of S. agalactiae strain NEM316 grown in vitro. A total of 227 genes with outlier expression were found (164 upregulated and 63 downregulated) between PJI sonicate fluid and in vitro conditions. Functional enrichment analysis showed genes involved in mobilome and inorganic ion transport and metabolism to be most enriched. Genes involved in nickel, copper, and zinc transport, were upregulated. Among known virulence factors, cyl operon genes, encoding β‐hemolysin/cytolysin, were consistently highly expressed in PJI versus in vitro. The data presented provide insight into S. agalactiae PJI pathogenesis and may be a resource for identification of novel PJI therapeutics or vaccines against invasive S. agalactiae infections.